Literature DB >> 22114301

Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D.

Matthijs M Versteegh1, Annemieke Leunis1, Jolanda J Luime2, Mike Boggild3, Carin A Uyl-de Groot1, Elly A Stolk1.   

Abstract

BACKGROUND: Responses on condition-specific instruments can be mapped on the EQ-5D to estimate utility values for economic evaluation. Mapping functions differ in predictive quality, and not all condition-specific measures are suitable for estimating EQ-5D utilities. We mapped QLQ-C30, HAQ, and MSIS-29 on the EQ-5D and compared the quality of the mapping functions with statistical and clinical indicators.
METHODS: We used 4 data sets that included both the EQ-5D and a condition-specific measure to develop ordinary least squares regression equations. For the QLQ-C30, we used a multiple myeloma data set and a non-Hodgkin lymphoma one. An early arthritis cohort was used for the HAQ, and a cohort of patients with relapsing remitting or secondary progressive multiple sclerosis was used for the MSIS-29. We assessed the predictive quality of the mapping functions with the root mean square error (RMSE) and mean absolute error (MAE) and the ability to discriminate among relevant clinical subgroups. Pearson correlations between the condition-specific measures and items of the EQ-5D were used to determine if there is a relationship between the quality of the mapping functions and the amount of correlated content between the used measures.
RESULTS: The QLQ-C30 had the highest correlation with EQ-5D items. Average %RMSE was best for the QLQ-C30 with 10.9%, 12.2% for the HAQ, and 13.6% for the MSIS-29. The mappings predicted mean EQ-5D utilities without significant differences with observed utilities and discriminated between relevant clinical groups, except for the HAQ model.
CONCLUSIONS: The preferred mapping functions in this study seem suitable for estimating EQ-5D utilities for economic evaluation. However, this research shows that lower correlations between instruments lead to less predictive quality. Using additional validation tests besides reporting statistical measures of error improves the assessment of predictive quality.

Entities:  

Mesh:

Year:  2011        PMID: 22114301     DOI: 10.1177/0272989X11427761

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  19 in total

1.  Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.

Authors:  Admassu N Lamu; Jan Abel Olsen
Journal:  Qual Life Res       Date:  2018-09-01       Impact factor: 4.147

2.  Predicting health utilities for children with autism spectrum disorders.

Authors:  Nalin Payakachat; J Mick Tilford; Karen A Kuhlthau; N Job van Exel; Erica Kovacs; Jayne Bellando; Jeffrey M Pyne; Werner B F Brouwer
Journal:  Autism Res       Date:  2014-09-25       Impact factor: 5.216

3.  Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.

Authors:  Hosein Ameri; Mahmood Yousefi; Mehdi Yaseri; Azin Nahvijou; Mohammad Arab; Ali Akbari Sari
Journal:  J Gastrointest Cancer       Date:  2020-03

4.  Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.

Authors:  Brett Doble; Paula Lorgelly
Journal:  Qual Life Res       Date:  2015-09-21       Impact factor: 4.147

5.  Mapping of the OAB-SF Questionnaire onto EQ-5D in Spanish Patients with Overactive Bladder.

Authors:  Miguel A Ruiz; Laura L Gutiérrez; Manuel Monroy; Javier Rejas
Journal:  Clin Drug Investig       Date:  2016-04       Impact factor: 2.859

6.  Do country-specific preference weights matter in the choice of mapping algorithms? The case of mapping the Diabetes-39 onto eight country-specific EQ-5D-5L value sets.

Authors:  Admassu N Lamu; Gang Chen; Thor Gamst-Klaussen; Jan Abel Olsen
Journal:  Qual Life Res       Date:  2018-03-22       Impact factor: 4.147

7.  An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences.

Authors:  Ralph Crott; Matthijs Versteegh; Carin Uyl-de-Groot
Journal:  Qual Life Res       Date:  2012-06-29       Impact factor: 4.147

8.  Mapping onto Eq-5 D for patients in poor health.

Authors:  Matthijs M Versteegh; Donna Rowen; John E Brazier; Elly A Stolk
Journal:  Health Qual Life Outcomes       Date:  2010-11-26       Impact factor: 3.186

9.  Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma.

Authors:  David T Arnold; Donna Rowen; Matthijs M Versteegh; Anna Morley; Clare E Hooper; Nicholas A Maskell
Journal:  Health Qual Life Outcomes       Date:  2015-01-23       Impact factor: 3.186

10.  Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients.

Authors:  Seon Ha Kim; Min-Woo Jo; Hwa-Jung Kim; Jin-Hee Ahn
Journal:  Health Qual Life Outcomes       Date:  2012-12-17       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.